A New Rapid and Quantitative Assay to Determine the Phytase Activity of Feed

por Willard, Eric C. D., Sundquist, Alfred, Glitsoe, Vibe, Sorbara, Jose Otavio, Tamez-Hidalgo, Paulina, Heine, Cornelia, Ricker, Tara, Lehmann, Martin, Bergman, Andre, Etheve, Stéphane, Chatelle, Claire V.
Publicado 2022

The Effects of Enzalutamide Monotherapy on Multiparametric 3T MR Imaging in Prostate Cancer

por Van der Roest, Rosanne CV., van Houdt, Petra J., Heijmink, Stijn WTPJ., de Jong, Jeroen, Bergman, André M., Zwart, Wilbert, van der Heide, Uulke A., van der Poel, Henk G.
Publicado 2016

Neutropenia and docetaxel exposure in metastatic castration‐resistant prostate cancer patients: A meta‐analysis and evaluation of a clinical cohort

por de Vries Schultink, Aurelia H. M., Crombag, Marie‐Rose B. S., van Werkhoven, Erik, Otten, Hans‐Martin, Bergman, Andre M., Schellens, Jan H. M., Huitema, Alwin D. R., Beijnen, Jos H.
Publicado 2019

A randomized two arm phase III study in patients post radical resection of liver metastases of colorectal cancer to investigate bevacizumab in combination with capecitabine plus ox...

por Snoeren, Nikol, Voest, Emile E, Bergman, Andre M, Dalesio, Otilia, Verheul, Henk M, Tollenaar, Rob AEM, van der Sijp, Joost RM, Schouten, Sander B, Rinkes, Inne HM Borel, van Hillegersberg, R
Publicado 2010

Prognostic factors in men with metastatic castration-resistant prostate cancer treated with cabazitaxel

por Belderbos, Bodine P.S., de Wit, Ronald, Hoop, Esther Oomen-de, Nieuweboer, Annemieke, Hamberg, Paul, van Alphen, Robbert J., Bergman, André, van der Meer, Nelly, Bins, Sander, Mathijssen, Ron H.J., van Soest, Robert J.
Publicado 2017

Randomized Phase III Study to Assess Efficacy and Safety of Adjuvant CAPOX with or without Bevacizumab in Patients after Resection of Colorectal Liver Metastases: HEPATICA study()(...

por Snoeren, Nikol, van Hillegersberg, Richard, Schouten, Sander B., Bergman, Andre M., van Werkhoven, Erikv, Dalesio, Otilia, Tollenaar, Rob A.E.M., Verheul, Henk M., van der Sijp, Joost, Borel Rinkes, Inne H.M., Voest, E.E.
Publicado 2017

The circadian cryptochrome, CRY1, is a pro-tumorigenic factor that rhythmically modulates DNA repair

por Shafi, Ayesha A., McNair, Chris M., McCann, Jennifer J., Alshalalfa, Mohammed, Shostak, Anton, Severson, Tesa M., Zhu, Yanyun, Bergman, Andre, Gordon, Nicolas, Mandigo, Amy C., Chand, Saswati N., Gallagher, Peter, Dylgjeri, Emanuela, Laufer, Talya S., Vasilevskaya, Irina A., Schiewer, Matthew J., Brunner, Michael, Feng, Felix Y., Zwart, Wilbert, Knudsen, Karen E.
Publicado 2021